1. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. 2016.
https://www.nice.org.uk/guidance/ta375/resources/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed-pdf-82602790920133
. Accessed 28 March 2017.
2. Moorkens E, Jonker-Exler C, Huys I, Declerck P, Simoens S, Vulto AG. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol. 2016;7:193.
https://doi.org/10.3389/fphar.2016.00193
.
3. Research and Market. Tumor necrosis factor inhibitors market and clinical pipeline outlook 2022. 2016.
http://www.researchandmarkets.com/research/ql452m/tumor_necrosis#
. Accessed 28 March 2017.
4. Health and Social Care Information Centre. Prescribing costs in hospitals and the community: England 2015/16. 2016.
http://www.content.digital.nhs.uk/catalogue/PUB22302/hosp-pres-eng-201516-report.pdf
. Accessed 20 July 2017.
5. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275.
https://doi.org/10.1371/journal.pone.0030275
.